



### Conference Co-Chairpersons

Dafna Bar-Sagi, New York University School of Medicine, New York, NY  
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY  
Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA  
Andrew M. Lowy, University of California – San Diego, San Diego, CA  
David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

There has been unprecedented progress in our understanding of pancreatic cancer in recent years. This new era has brought us many extraordinary advances in the basic science of pancreatic cancer, ranging from genomics to the exciting new technologies that are rapidly changing our approaches to the prevention, diagnosis, and treatment of this disease. As a follow-up to the very successful AACR Special Conference on Pancreatic Cancer in 2012, this conference will once again engage the world leaders in pancreatic cancer research and provide ample time for discussion.

The AACR would like to thank the following organizations for their generous support of this conference.

### Lead Supporters



### Professional Educational Grants




The AACR thanks the following organizations for their generous support of the travel awards provided at this conference.

### Award Supporters



Center to  
Reduce  
Cancer Health  
Disparities



## Conference Program

### Sunday, May 18

---

**7:00 p.m.-8:30 p.m. Opening Plenary Session**  
Celestin Ballroom

**Dynamics and evolution of pancreatic cancer from inception to invasion**  
Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY

**Remarks**  
Robb Lamont, Survivor-Advocate, Tampa Bay, FL

**8:30 p.m.-10:00 p.m. Opening Reception**  
Bywater Pool Deck & Bar

### Monday, May 19

---

**7:00 a.m.-8:00 a.m. Continental Breakfast**  
Storyville Hall

**8:00 a.m.-10:30 a.m. Plenary Session 1: Development**  
Celestin Ballroom  
*Session Chairperson: Howard C. Crawford, Mayo Clinic Florida, Jacksonville, FL*

**Cellular origins of pancreatic ductal adenocarcinoma**  
Maïke Sander, University of California - San Diego, San Diego, CA

**Pancreatic cancer may be initiated by Dclk1+ cells and regulated by adrenergic signaling**  
Timothy C. Wang, Columbia University, New York, NY

**Translating genetic discoveries to patient care**  
Ralph H. Hruban, Johns Hopkins University, Baltimore, MD

**Identification and characterization of factors required for KRAS-driven pancreatic tumorigenesis**  
Brian C. Lewis, University of Massachusetts Medical School, Worcester, MA

**Downregulation of PTF1A is a crucial and rate-limiting step in pancreatic cancer initiation\***  
Nathan Michael Krahn, University of Utah, Salt Lake City, UT

**DCLK1-positive cells represent a unique pancreatic cellular lineage in a subset of intraductal papillary mucinous neoplasms\***  
Gloria H. Su, Columbia University Medical Center, New York, NY

\*Short talks from proffered papers.

**10:30 a.m.-10:50 a.m. Break**  
Storyville Hall

**10:50 a.m.-1:05 p.m. Plenary Session 2: Inflammation/Stroma**  
Celestin Ballroom  
*Session Chairperson: Timothy C. Wang, Columbia University, New York, NY*

**Innate immune signaling in pancreatic tumor microenvironment**  
George Miller, New York University School of Medicine, New York, NY

**Tumor-stroma dynamics in pancreatic cancer**  
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

**Vitamin D: Shining light on pancreatic cancer**  
Ronald M. Evans, Salk Institute for Biological Sciences, La Jolla, CA

**Targeting the microenvironment: Challenges and opportunities**  
George A. Fisher, Stanford Cancer Center, Stanford, CA

**Mesenchymal stem cells in pancreatic cancer possess unique properties in promoting tumor growth and metastasis\***  
Meghna Waghray, University of Michigan, Ann Arbor, MI

**1:05 p.m.-2:30 p.m. Lunch Break (lunch on your own)**

**2:30 p.m.-4:45 p.m. Plenary Session 3: Impacts of Heterogeneity in Tumor Progression**  
Celestin Ballroom  
*Session Chairperson: Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY*

**Generation of intratumoral heterogeneity via RNA-DNA differences in pancreatic cancer**  
Andrew Rhim, University of Michigan Medical School, Ann Arbor, MI

**Stem cell signals in cancer growth and progression**  
Tannishtha Reya, University of California - San Diego, San Diego, CA

**Acinar cell transdifferentiation sets the stage for early tumor heterogeneity**  
Howard C. Crawford, Mayo Clinic Florida, Jacksonville, FL

**Clonal composition and clonal selection during PanIN progression\***  
Kelly J. Lafaro, Johns Hopkins Hospital, Baltimore, MD

**p120 catenin mediated epithelial-to-mesenchymal plasticity determines the metastatic potential of pancreatic ductal adenocarcinoma\***  
Maximilian Reichert, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

**Remarks**  
Kerri Kaplan, The Lustgarten Foundation, Bethpage, NY

**Remarks**  
Julie M. Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA

\*Short talks from proffered papers.

**4:45 p.m.-7:15 p.m. Poster Session A**  
Storyville Hall

## **Tuesday, May 20**

---

**7:00 a.m.-8:00 a.m. Continental Breakfast**  
Storyville Hall

**8:00 a.m.-10:00 a.m. Plenary Session 4: Diagnostics**  
Celestin Ballroom  
*Session Chairperson: Andrew M. Lowy, University of California - San Diego, San Diego, CA*

**Diagnosis and treatment of pancreas cancer**

Raghu Kalluri, The University of Texas MD Anderson Cancer Center, Houston, TX

**Circulating tumor DNA**

Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

**New methods of PET imaging pancreas cancer**

Jason S. Lewis, Memorial Sloan Kettering Cancer Center, New York, NY

**The ampullary adenocarcinoma, its molecular characterization and differentiation from the pancreatic ductal adenocarcinoma, duodenal adenocarcinoma, and cholangiocarcinoma\***

Marie-Claude Gingras, Baylor College of Medicine, Houston, TX

**Transcriptome meta-analysis identifies new 5-gene classifier for early detection of pancreatic cancer\***

Towia Aron Libermann, Beth Israel Deaconess Medical Center, Boston, MA

**10:00 a.m.-10:30 a.m. Break**  
Storyville Hall

**10:30 a.m.-12:30 p.m. Plenary Session 5: Metabolism**  
Celestin Ballroom  
*Chairperson: Alec C. Kimmelman, Dana-Farber Cancer Institute, Boston, MA*

**Transcriptional control of the autophagy-lysosome system drives amino acid metabolism in pancreatic cancer**

Nabeel M. Bardeesy, Massachusetts General Hospital Cancer Center, Boston, MA

**Obesity, inflammation, and pancreatic cancer**

Guido E.M. Eibl, UCLA David Geffen School of Medicine, Los Angeles, CA

**The role of autophagy in pancreatic cancer development**

Kevin M. Ryan, Cancer Research UK Beatson Institute, Glasgow, United Kingdom

**Pulling out all the stops: Exploiting macropinocytosis inhibition for the treatment of pancreatic cancer\***

Cosimo Comisso, New York University School of Medicine, New York, NY

**Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression\***

Aram Hezel, University of Rochester, Rochester, NY

**12:30 p.m.-3:00 p.m. Poster Session B and Lunch**

Storyville Hall

**3:00 p.m.-5:00 p.m. Plenary Session 6: Immunology**

Celestin Ballroom

*Session Chairperson: Dafna Bar-Sagi, New York University School of Medicine, New York, NY*

**Harnessing the immune reaction associated with pancreas carcinoma for therapy**

Gregory L. Beatty, University of Pennsylvania, Philadelphia, PA

**The basis of immune suppression in murine pancreatic ductal adenocarcinoma**

Douglas T. Fearon, Cancer Research UK Cambridge Research Institute, Cambridge, United Kingdom

**Innate immune cell PI3K gamma as a target for suppression of pancreatic ductal carcinoma**

Judith A. Varner, Moores Cancer Center, San Diego, CA

**Re-engineering immunity to treat pancreas cancer\***

Ingunn M. Stromnes, Fred Hutchinson Cancer Research Center, Seattle, WA

**CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice\***

Yaqing Zhang, University of Michigan, Ann Arbor, MI

**Wednesday, May 21**

---

**7:00 a.m.-8:00 a.m. Continental Breakfast**

Storyville Hall

**8:00 a.m.-10:00 a.m. Plenary Session 7: New Therapies**

Celestin Ballroom

*Session Chairperson: Eileen O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY*

**Targeting Ras**

Gregory L. Verdine, Harvard University, Cambridge, MA

**Oncogenic Kras and the pancreatic cancer microenvironment**

Marina Pasca di Magliano, University of Michigan, Ann Arbor, MI

**Targeting K-Ras signaling in pancreatic cancer**

Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain

**Identification of tumorigenic cells and therapeutic targets in pancreatic neuroendocrine cancers\***

Geoffrey Wayne Krampitz, Stanford University School of Medicine, Stanford, CA

**Pancreatic tumor stem cells resistant to inhibition of oncogenic signaling are dependent on mitochondrial function\***

Andrea Viale, The University of Texas MD Anderson Cancer Center, Houston, TX

\*Short talks from proffered papers.

**10:00 a.m.-10:30 a.m. Break**  
Storyville Hall

**10:30 a.m.-12:15 p.m. Plenary Session 8: Clinical Science Trials**  
Celestin Ballroom  
*Session Chairperson: David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY*

**Pancreatic adenocarcinoma and altered whole-body metabolism**  
Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, MA

**Clinical trials in locally advanced pancreatic cancer (LAPC)**  
Christopher H. Crane, The University of Texas MD Anderson Cancer Center, Houston, TX

**BRCA-mutated pancreas adenocarcinoma: Emerging therapeutic implications**  
Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY

**PTEN-Long and gemcitabine combination treatment as a therapeutic for pancreatic cancer\***  
Roshan Ara Ahmed, Columbia University Medical Center, New York, NY

\*Short talks from proffered papers.